NCQA Releases White Paper on Improving Osteoporosis Care
July 14, 2022 19:00 ET
|
NCQA
WASHINGTON, July 14, 2022 (GLOBE NEWSWIRE) -- The National Committee for Quality Assurance (NCQA) today announced the release of a new white paper titled, "Improving Osteoporosis Care," with...
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
May 16, 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 08:00 ET
|
Entera Bio Ltd.
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
May 05, 2022 08:00 ET
|
Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
Entera Bio to Report First Quarter 2022 Financial Results on May 12
April 28, 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
March 22, 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
March 08, 2022 06:30 ET
|
Entera Bio Ltd.
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
March 03, 2022 09:50 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Bone Health Technologies Closes $2.5 Million Funding Round and Appoints New Board Members
May 03, 2021 10:00 ET
|
Bone Health Technologies
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of technologies for improving bone health, announces today the close of its $2.5 million funding round...
Bone Health Technologies Appoints Laura Yecies as Chief Executive Officer
April 07, 2021 12:11 ET
|
Bone Health Technologies
SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of progressive new therapies for improving bone health, today announced the appointment of...